Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond.

IF 8.2 1区医学 Q1 HEMATOLOGY

Haematologica Pub Date : 2024-11-21 DOI:10.3324/haematol.2024.285636

Phaik Ju Teoh, Mun Yee Koh, Constantine Mitsiades, Sarah Gooding, Wee Joo Chng

引用次数: 0

Abstract

Acquired resistance to immunomodulatory drugs (IMiDs) remains a significant unmet need in the treatment landscape of multiple myeloma (MM). CRBN pathway-dependent mechanisms are known to be vital contributors to IMiD resistance; however, they may account for only a small proportion. Recent research has unveiled additional mechanisms of acquired IMiD resistance that are independent of the CRBN pathway. In this review, we provide a comprehensive overview of the existing work on IMiD resistance in MM, focusing specifically on the emerging evidence of CRBN pathway-independent mechanisms. Finally, we discuss the plausible actionable strategies and outlook for IMiD-based therapies moving forward.

查看原文本刊更多论文

多发性骨髓瘤对免疫调节药物的抗药性：脑瘤通路及其他。

对免疫调节药物（IMiDs）的获得性耐药性仍然是多发性骨髓瘤（MM）治疗领域尚未满足的一个重要需求。众所周知，CRBN通路依赖性机制是导致IMiD耐药的重要因素；然而，它们可能只占一小部分。最近的研究揭示了独立于 CRBN 通路的获得性 IMiD 耐药性的其他机制。在这篇综述中，我们全面概述了有关 MM 中 IMiD 耐药性的现有研究，特别关注了新出现的不依赖 CRBN 通路机制的证据。最后，我们讨论了基于 IMiD 的疗法的合理可行策略和前景展望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Haematologica 医学-血液学

CiteScore

14.10

自引率

2.00%

发文量

349

审稿时长

3-6 weeks

期刊介绍： Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.